自身免疫性药物研发商演生潮完成数亿元A轮融资，凯辉基金领投

Core Insights - The article discusses the recent A-round financing of Yanshengchao, a company focused on developing autoimmune disease treatments, led by the Sequoia Capital's Sanofi Sequoia Pharmaceutical Innovation Fund [2][3] Company Overview - Yanshengchao (Beijing) Biotechnology Co., Ltd. was established in May 2022 and specializes in innovative biotechnology for autoimmune and chronic inflammatory diseases, focusing on the CXCR3 pathway [3][4] - The company’s core candidate drug, YSC001, is designed to block the binding of CXCR3 to its ligands, reducing the accumulation of abnormal immune cells at disease sites, thus providing new treatment options for conditions like rheumatoid arthritis and vitiligo [3][4] Research and Development Focus - The financing will primarily support the advancement of Yanshengchao's core pipeline related to the CXCR3 pathway, as well as preclinical development and team building [3][5] - The company aims to create a comprehensive research and development system around the CXCR3 axis, with the capability to advance development and collaboration according to global standards [5] Competitive Advantages - Yanshengchao benefits from a strong scientific foundation rooted in Tsinghua University's immunology research, providing a systematic understanding of key mechanisms related to T/B cell fate and immune memory [5] - The company has a clear product strategy focusing on first-in-class innovations rather than marginal improvements on existing targets, informed by scientific research and clinical feedback [5] - The organizational structure includes both academic leaders and industry veterans, ensuring a balanced approach between scientific frontiers and practical development [5] Future Collaboration - Sequoia Capital and Sanofi plan to leverage their strengths in global industry ecosystems and clinical translation to support Yanshengchao in accelerating the transition of its innovative therapies from the lab to global clinical practice [6]